Skip to main content

Lyme Disease

6
Pipeline Programs
8
Companies
9
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
5
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 10 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
1
1
AntibioticsPhase 32 trials
Lyme Disease XenodiagnosisPhase 11 trial
Evaluation and Follow-up of People With Tick-borne DiseasesN/A1 trial
Evaluation, Treatment, and Follow-up of Patients With Lyme DiseaseN/A1 trial
Active Trials
NCT04318925Withdrawn0Est. Nov 2023
NCT00028080Recruiting500
NCT01143558Completed45Est. Dec 2014
+2 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
3
VLA15Phase 31 trial
VLA15Phase 31 trial
VLA15Phase 31 trial
Active Trials
NCT05477524Completed12,546Est. Jan 2026
NCT07500506Recruiting1,712Est. Dec 2026
NCT05634811Completed3,547Est. Jul 2025
Valneva
ValnevaAustria - Vienna
1 program
1
VLA15Phase 3
IQVIA
IQVIADURHAM, NC
1 program
T-Detect LymeN/A
Adaptive Biotechnologies
1 program
T-Detect LymeN/A
Moderna
ModernaCAMBRIDGE, MA
1 program
mRNA-1975PHASE_1_2RNA Therapeutic1 trial
Active Trials
NCT05975099Completed807Est. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Allergy TherapeuticsAntibiotics
PfizerVLA15
PfizerVLA15
PfizerVLA15
Allergy TherapeuticsAntibiotics
ModernamRNA-1975
Allergy TherapeuticsLyme Disease Xenodiagnosis
Allergy TherapeuticsEvaluation and Follow-up of People With Tick-borne Diseases
Allergy TherapeuticsEvaluation, Treatment, and Follow-up of Patients With Lyme Disease

Clinical Trials (9)

Total enrollment: 19,312 patients across 9 trials

NCT00000937Allergy TherapeuticsAntibiotics

Study and Treatment of Post Lyme Disease (STOP-LD)

Est. completion: Nov 200555 patients
Phase 3Completed
NCT07500506PfizerVLA15

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

Start: Apr 2026Est. completion: Dec 20261,712 patients
Phase 3Recruiting
NCT05634811PfizerVLA15

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Start: Dec 2022Est. completion: Jul 20253,547 patients
Phase 3Completed
NCT05477524PfizerVLA15

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Start: Aug 2022Est. completion: Jan 202612,546 patients
Phase 3Completed
NCT07599865Allergy TherapeuticsAntibiotics

Periprosthetic Joint Infection Bubble Study

Start: Jun 2026Est. completion: Jun 2030100 patients
Phase 2Not Yet Recruiting
NCT05975099ModernamRNA-1975

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

Start: Jul 2023Est. completion: May 2025807 patients
Phase 1/2Completed
NCT01143558Allergy TherapeuticsLyme Disease Xenodiagnosis

Searching for Persistence of Infection in Lyme Disease

Start: Nov 2010Est. completion: Dec 201445 patients
Phase 1Completed
NCT04318925Allergy TherapeuticsEvaluation and Follow-up of People With Tick-borne Diseases

Evaluation and Follow-up of People With Tick-borne Diseases

Start: Nov 2023Est. completion: Nov 20230
N/AWithdrawn
NCT00028080Allergy TherapeuticsEvaluation, Treatment, and Follow-up of Patients With Lyme Disease

Evaluation, Treatment, and Follow-up of Patients With Lyme Disease

Start: Jan 2002500 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 19,312 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.